secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001193125-22-214871
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial
------------------------------------------------------------------------------

- Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.
- Cash and equivalents $684.5M at June 30, 2022, down from $764.4M at Dec 31, 2021.
- Bemnifosbuvir to advance to global late-stage trial for COVID-19 in Q4 2022; primary endpoint hospitalization/death in high-risk patients.
- MORNINGSKY Phase 3 missed primary symptom alleviation endpoint but showed 71% reduction in hospitalization (exploratory p=0.047).
- AT-752 for dengue and HCV combo trial advancing; initial results expected Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/0001193125-22-214871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/d356253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-214871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer